Scott Byrd, Chief Executive Officer
Mr. Byrd has over 25 years of experience in the pharmaceutical industry, most recently serving as President and Chief Operating Officer of Acacia Pharma, Inc. Prior to Acacia, he was Senior Vice President and Chief Commercial Officer of Cadence Pharmaceuticals from 2009 until its acquisition by Mallinckrodt Pharmaceuticals for $1.4 billion in 2014. At Cadence, Mr. Byrd built the company’s commercial and supply-chain infrastructure and led the launch of OFIRMEV®, a market-leading non-opioid injectable analgesic. Earlier in his career, he served in a variety of roles of increasing responsibility at Eli Lilly and Company, including sales, marketing, development, manufacturing, and strategic planning. Mr. Byrd is a member of the board of directors for Acacia Pharma Ltd. He holds a B.S. in mechanical engineering from Bradley University and an MBA from Harvard Business School.
Gordon McMurray, PhD, Chief Scientific Officer
Dr. McMurray joined Outpost from Pfizer where he was most recently Head of Pharmacology for the Neuroscience and Pain Research Unit. He previously served in multiple Research Project and Team Leader roles in both the Pain and Sensory Disorders Research Unit and the Genitourinary and Sexual Dysfunction Research Unit. During that time, Dr. McMurray led multiple research programs targeting important urologic diseases and conditions, including stress urinary incontinence, overactive bladder and interstitial cystitis. Prior to Pfizer, he was Lecturer in Pharmacology and Laboratory Head in the Department of Pharmacology at Oxford University where he was a member of the Oxford Continence Group. Dr. McMurray holds a B.Sc. and Ph.D. from Queen’s University Belfast.
Ian Mills, BM, BCh, DM, Chief Medical Officer
Dr. Mills joined Outpost from Mitsubishi Tanabe Pharma Europe, where he was Head of Clinical Development. Prior to Mitsubishi, he was with Pfizer for more than 15 years in a variety of clinical and development leadership roles, including six years as Clinical Head of Genitourinary and Women’s Health and most recently as Vice President and Global Clinical Head for the Innovative Pharma Business. He has provided leadership to more than 20 urology projects spanning Phases 1-4, led the submissions of five products across multiple therapeutic areas for approval in major markets, and guided two pharmaceutical products to FDA approval for urology indications. Dr. Mills received his M.A. in Natural Sciences from Cambridge University and his medical degree (B.M., B.Ch) from Oxford University. He was awarded a medical doctorate (D.M.) from Oxford for his research on the pathophysiology of overactive bladder.
Gale Kennedy, Vice President, Clinical Development
Ms. Kennedy most recently served as Senior Director, Clinical Science at Takeda. During that time, she had clinical leadership responsibilities for multiple clinical-stage urology programs, including OP-233 (formerly TAK-233). Prior to Takeda, Ms. Kennedy was Programme Director at Plethora Solutions where she led Phase III development for a sexual dysfunction program. Earlier in her career, she held roles of increasing responsibility in clinical pharmacology and clinical development at Ono Pharmaceutical, AstraZeneca, and Sanofi. Ms. Kennedy holds a B.Sc. in Biochemistry and Pharmacology from the University of Strathclyde.
Mike Ramsay, Vice President, Manufacturing
Mr. Ramsay joined Outpost from The Medicines Company which he joined through the acquisition of Incline Therapeutics where he was Senior Vice President, Manufacturing and Supply Operations. Prior to Incline, he was Senior Vice President, Manufacturing Operations at Cell Genesys with responsibility for three GMP manufacturing facilities. Previously, Mr. Ramsay served as Vice President, Transdermal Manufacturing at ALZA Corporation. He has also held various positions with SEQUUS Pharmaceuticals, including Vice President, Manufacturing Operations, as well as various positions at Syntex Corporation focusing on manufacturing, product development and regulatory affairs. Mr. Ramsay holds a Bachelor of Pharmacy degree from the University of Nottingham.
Board of Directors
Tadataka (Tachi) Yamada, MD, Chairman, Outpost Medicine
Dr. Yamada is a Venture Partner at Frazier Healthcare Partners. He was previously Executive Vice-President, Chief Medical & Scientific Officer and a Board Member of Takeda Pharmaceuticals. He joined Takeda after serving as President of the Bill & Melinda Gates Foundation Global Health Program where he managed $9 billion in programs directed at addressing major health challenges of the developing world. Previously, he had served as Chairman, Research and Development and a Member of the Board of GlaxoSmithKline and before that as Chair of the Department of Internal Medicine and Physician-in-Chief at the University of Michigan Medical Center. Dr. Yamada holds a bachelor’s degree in history from Stanford University and obtained his M.D. from New York University School of Medicine. In recognition of his contributions to medicine and science he has been elected to membership in the National Academy of Medicine (US), the Academy of Medical Sciences (UK) and the National Academy of Medicine (Mexico) and he has received an honorary appointment as Knight Commander of the Most Excellent Order of the British Empire (KBE). He is a Past-President of the Association of American Physicians and of the American Gastroenterological Association and he has served as a member of the President’s Council of Advisors on Science and Technology. He is currently Vice-Chair of the Council of the National Academy of Medicine and serves on the Board of Directors of Agilent Technologies and the Clinton Health Access Initiative.
Scott Byrd, CEO, Outpost Medicine
Daniel Estes, PhD, Principal, Frazier Healthcare Partners
Dr. Estes joined Frazier Healthcare Partners in 2011 and focuses on investments in both development-stage and commercial-stage pharmaceutical companies. He serves on the board of Semnur Pharmaceuticals and is a board observer at Millendo Therapeutics (formerly Atterocor). He has also been involved in Frazier’s investments in Acerta (acquired by AstraZeneca), Cidara (NASDAQ: CDTX), ProNAi (NASDAQ: DNAI), Allena, Alcresta, Tobira (NASDAQ: TBRA), and Precision Dermatology (acquired by Valeant). Prior to joining Frazier, Dr. Estes was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised global pharmaceutical and biotechnology companies on R&D strategy and business development strategy. He received his Ph.D. in Biomedical Engineering from the University of Michigan, where his doctoral research focused on studying the roles of potassium ion channels on human T cells in human autoimmune diseases. Dr. Estes has authored nine papers in peer-reviewed journals and received several fellowships from the National Institutes of Health. He also holds a B.S. in Electrical Engineering from Stanford University, where he is a member of Tau Beta Pi.
Terry Gould, Partner and Head of Direct Investments, Adams Street Partners
Mr. Gould is a Partner and Head of Direct Investments at Adams Street Partners. He invests in venture and growth-oriented companies with a focus on the healthcare space. Mr. Gould sits on the Boards of Directors of Aptinyx, Corvus, LifeBond, OncoMed (NADSAQ: OMED), and Orbus Pharmaceuticals, and is a Board Observer at Millendo. He is a former board member at CombiChem, INC Research, Incline Therapeutics, and Proteus Digital Health. He is responsible for several other successful investments including Heartport, Jazz Pharmaceuticals, Naurex Pharmaceuticals, NxStage Medical, Pharmacyclics, Rempex Pharmaceuticals, Revivant, Spinal Dynamics and Vivant Medical. Before joining Adams Street Partners in 1994, Mr. Gould was with Trinity Ventures, Ltd. and spent five years as a management consultant, including experience with the Boston Consulting Group, an international strategy consulting firm. He also has experience as a founder and executive in two successful entrepreneurial companies.
Terry is Chairman of the Adams Street Partners Venture/Growth Investment Committee, a member of the Adams Street Co-Investment/Private Credit Investment Committee, and a member of the Adams Street Partners Executive Committee.
Peter Moldt, PhD, Partner, Novo Ventures
Peter is a Partner of Novo Ventures (US) Inc. which he joined in 2012. He is chairman of the Board of Directors of Allakos Inc., and a member of the Board of Directors of Corvus Pharmaceuticals Inc., Bolt Therapeutics, E-Scape Bio. Spruce Biosciences and Tioma Therapeutics. Previously, he was a board member of Cytochroma Inc., HemoFocus ApS, Neurokey A/S and Orphazyme ApS. From 2009-2012, Peter was employed with Novo A/S as a partner in Novo Ventures. In 2004, Peter co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000-2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development. Peter holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy. He has also been a post doc with Yale University's department of organic chemistry.
David Socks, Venture Partner, Frazier Healthcare Partners
Mr. Socks serves as a Venture Partner with Frazier Healthcare Partners, a life science venture capital firm, where he focuses on company creation. As part of that role, he previously served as the founding CEO of Outpost Medicine. Prior to joining Frazier he co-founded Incline Therapeutics in 2010 and served as its President and Chief Operating Officer until its sale to The Medicines Company in 2013 for up to $390 million. Mr. Socks also co-founded Cadence Pharmaceuticals in 2004 and served as its Senior Vice President, Corporate Development and Strategy. Cadence completed its IPO in 2006, received FDA approval for OFIRMEV (acetaminophen injection) in 2010, and was acquired by Mallinckrodt in 2013 for $1.3 billion. Previously, Mr. Socks was a Venture Partner at Windamere Venture Partners, where he co-founded companies including Cadence, Somaxon Pharmaceuticals (acquired by Pernix Therapeutics) and Verus Pharmaceuticals (acquired by AstraZeneca and Shionogi/Sciele). Previously, he worked in private equity and management consulting. Mr. Socks holds a B.S. from Georgetown University and an M.B.A. from Stanford University.
Chen Yu, MD, Managing Partner, Vivo Capital
Dr. Yu is a Managing Partner with Vivo Capital where he invests in both private and public pharmaceutical and medical device companies in the US and China. He has extensive operating experience with leadership roles at both private and public companies, including Sagent Pharmaceuticals (SGNT), China KangHui (KH), and aQuantive (AQNT). Notably, Dr. Yu has played a leading industry role in facilitating cross border deals between emerging market and US healthcare companies. As Chief Business Officer at China KangHui (KH), a leading China based orthopedic company, he helped take the company public on the New York Stock Exchange in 2010 and ultimately led negotiations during the sale to Medtronic for $816 MM in 2012. Most recently, Dr. Yu served as Chief Operating Officer at Sagent Pharmaceuticals (SGNT), which partners with leading companies across Asia and Europe. Dr. Yu currently serves or has served on the boards of several life science companies in both the US and China, including Sentre Heart (US), Rempex (Acquired by MDCO), Nora Therapeutics (US), Jian Rui Bao (China), GMT Medical (China), and Synaptic Medical (China). Other representative investments include Trauson (acquired by Stryker for $764 MM), Durata (DRTX), Achillion (ACHN), Cubist (CBST), and Ocera (OCRX). Dr. Yu is also active in the community and currently serves on the California Leadership Council for the Nature Conservancy, an environmental non-profit with global reach. He was also previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.